Advisor Group Holdings, Inc. Candel Therapeutics, Inc. Transaction History
Advisor Group Holdings, Inc.
- $39.8 Billion
- Q4 2024
A detailed history of Advisor Group Holdings, Inc. transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 27 shares of CADL stock, worth $230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27Holding current value
$230% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
64Shares Held
8.14MCall Options Held
112KPut Options Held
130K-
Northpond Ventures, LLC1.94MShares$16.5 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$11.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$7.01 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA754KShares$6.42 Million0.5% of portfolio
-
Halter Ferguson Financial Inc. Carmel, IN681KShares$5.8 Million2.42% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $246M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...